Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
and now that they disappeared off of my tdameritrade account I worry that I will never see them again. Everything about this company is a cluster f
I was waiting for their vaccine...don't think I care to try it, now.
How in the world, Mr Moscato, could a symbol be approved by SEC and applied to your dividend stock WITHOUT YOUR KNOWLEDGE? How, also, could 80% of the shares be restricted and the other 20% available to market? I called my broker, TDA, and the number of shares I was allowed sell worked out to 20% of my holding. How in the world did I sit on a numerical identification for 10's of months and my shares were suddenly assigned a symbol, NUGX - at the same time it was being published that this was all about to happen??... and you, Mr Moscato and the company WERE COMPLETELY IN THE DARK?? Now, just as suddenly, my holding has just been reduced by the exact number of shares that I was not allowed to trade. i. e. 80% of my shares are instantly GONE! Ironic that when I called TDA about shares I could not sell (by the way I never sold any), after leaving me on hold for several minutes, they told me that it originated with "the issuer of the shares".
Can someone please tell me who created the NUGX symbol in the first place?
The shares of NUGX was given to us via the dividend shares from GNBT.
Mr. Moscato continued, “It has come to the attention of the management of Generex Biotechnology Corporation (the “Company”) that certain shares of common stock of its subsidiary, NuGenerex Immuno-Oncology, Inc. (“NuGenerex”) has been actively traded in the OTC pink sheets under the symbol NUGX. This trading symbol was created without the Company’s or NuGenerex’s knowledge. All of the trades under the NUGX symbol have occurred without any authorization from or participation by the Company. As previously announced, NGIO has applied for a Nasdaq listing and such application is still active. NuGenerex has reserved NGIO as its NASDAQ trading symbol. If NuGenerex is approved for listing, the NUGX symbol will no longer be active.
Totally agree.
This stock's application to NASDAS has submitted about a month a so ago. It will be in a bigger investors pool than it is now, and so the pps will also be a lot higher than it is now as well.
I grabbed some more this morning at .89.
Go luck to all of you. Go NUGX.
Yep, the stock is not yet , so NUGX may be not as its representing for trade . Hopefully it will be on NASDAQ soon, and should be more than $5 when debut.
https://nugenerexio.com/about/
Looks promising....
thanks bwolfy2002. Good to know. I have Fidelity also.
I think Generex is Canadian... thus the spin-off would also be too.
Maybe that is it?
That usually is a number for international companies to track?
$NUGX
Guys -- I tried to enter a BUY order via the order system on E-trade for NGUX. It sat there and sat there, even though my price was at the ask. I cancelled the order, went over to my portfolio page, clicked on BUY from there on NUGX and was able to buy shares.
So if you key in NUGX, then try to buy, the system does not recognize it. However if you go to the line item on your portfolio and click on BUY (or SELL if you want to sell), it will work.
I noticed when you do that, the stock is not just NUGX, but NUGX NUGENEREX IMMUNO ONCOLOGY INC COM. NUGX alone returns no results.
It's strange, but it's a workaround. Not sure if other brokers are working this way or not.
I can confirm that through Fidelity I am able to buy and sell NUGX.
why does everyone sell?
I found isin in other site is US67053X1028 anyway thanks
Very helpful. Thanks
I also have TDA. I also received a reject when I tried to sell. I called TDA. They left me on hold a short time and got back with: NUGX has restricted what turned out to be 80% of my shares. The other 20% are available for selling. I've left it alone for the time being, cuz I missed the price I wanted to sell at. I haven't tried to buy, so I don't know about that scenario. Hope this is helpful.
This lookup tool couldn't find one:
https://stockmarketmba.com/symbollookup.php
Not sure if that is normal for gray/pink OTC's or if it is too new.
docj, gotcha. Symbol will eventually be NGIO. For now NUGX gone rogue.
They have pulled them from the SEC's EDGAR site for NuGenerex Immuno-Oncology I assume.
Doc,
If GNBT & NGIO have nothing to do with NUGX, then why are the 8K's and yearly listed under NUGX with the OTC?
You have to get with a live broker and they will get with someone in operations to get the shares unrestricted. You will have to file a request and pay a fee.
Generex provided the shares in a "jumbo certificate" leaving it up to the brokers to deal with it. Some did some didn't but they have a process to address. Generex and NuGenerex have nothing to do with it.
I bought through TD yesterday
I have TD. My orders reject as soon as I enter them
I can and did buy!!! Schwab
Is this why we can't buy or sell shares?
YIKES!!! Thanks DOCJ..u r da man!!!
The trading of NGUX is not part of the IPO and was not done with the approval of Generex or NuGenerex. I have posted this on other boards. Call Joe and he will explain.
This is not the IPO of NGIO. This NGUX is a rogue deal between dividend holder and and a broker dealer and has nothing to do with the company Nugenerx I-O.
Hey. Check with your broker but Schwab tells me the initial problem is not with the first dividend payout but the second. My first dividend shares are shown as tradeable, and I did sell #5 shares just to make sure. Bought some also.
Generex provided the shares in a "jumbo certificate" to the brokers along with a list of shareholders and number of shares they should get. Unfortunately the brokers did not all immediately break up the certificate into individual lots although they did credit most accounts with restricted shares. Whatever broker you talk to will likely have to research what to do but a request will have to be filed and a small fee paid. Mine is $80. Most brokers have never dealt with this very unique situation.
Good question. I have no freaking idea. And on top of that it still has a cuspid number in my Fidelity account. Completely blindsided me.
What the hell did it IPO at? 12 cents?
Don't get it... they lost me on that one.....
Docj I tried to sell a few on TDA my shares are restricted for some reason. I received them from last years dividend. Do you know anything. Thanks in advance.
Nugenerex Immuno Oncology Inc Common Stock (PC) OTC BBN NUGX
$3.00 up 2.90 up (2,900.00%)
Not Bad :)
Hi DOCJ, how are you?, you may know some thing about the NUGX status listing on NASDAD, don't you?
Someone just ask about it. I am not know so sure about it, why it is trading now as a Pink instead?
Thanks in advance DOCJ.
I am not so sure, I don't think it is IPO yet. The parent company GNBT just turned the application for NASDAD, but I haven't heard the status of it.
Maybe someone may know some thing.
Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Complete Vaccine™ Development Program
February 24, 2021
Ii-Key-SARS-CoV-2 vaccine generates vaccine-specific antibodies and T cell responses in a transgenic mouse model
The Ii-Key vaccine elicits both CD4+ T Helper cell (Th1) and CD8+ responses that are necessary for long-term immune memory
Initiated discussions with a major research institution on licensing therapeutic antibodies against SARS-CoV-2
MIRAMAR, Fla., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has completed the mouse immunogenicity study with transgenic mice that have been genetically engineered with a gene from the human immune system called the DR4 human leukocyte antigen (HLA) allele, which is one of hundreds of alleles in the human immune system. HLAs are proteins - or markers -found on most cells in your body. Your immune system uses these markers to recognize which cells belong in your body and which do not. So, for example, HLA is used to match patients and donors for bone marrow or organ transplants. The Ii-Key is specific for human HLA, so therefore does not work in other species, making it difficult to evaluate vaccine efficacy in animal models. The DR4 transgenic mouse provides an opportunity to evaluate the ability of Ii-Key vaccines to generate immune responses in an animal model, recognizing that the DR4 allele is only one of dozens of human HLA epitopes contained in the Ii-Key-SARS-CoV-2 vaccine.
The results of the mouse immunogenicity study demonstrated that the Ii-Key vaccine in combination with the adjuvant produced antibodies that are directed against the Ii-Key-SARS-CoV-2 epitopes as measured by ELISA assay. T cells from the mice reacted strongly to stimulation by the Ii-Key vaccine in ex vivo studies of the mouse spleen cells which contain T and B cells, dendritic cells and macrophages, which have different immune functions. These results in a mouse model of the human immune system indicate the potential for Ii-Key-SARS-CoV-2 to be a Complete Vaccine™, though the true potential can only be determined in human clinical trials.
A Complete Vaccine™is designed to regulate the immune system to provide a targeted, neutralizing antibody response without generating off-target, non-neutralizing antibodies that can lead to antibody dependent enhancement of disease (ADE); further a complete vaccine should activate the appropriate T cell responses to yield long-term immune memory without activating detrimental Th2 responses that have been associated with immune-related complications of COVID-19 disease.
Joseph Moscato, President & CEO of Generex stated, “We are preparing our IND submission for Phase I and II human clinical trials to evaluate safety and immunogenicity of the Ii-Key vaccine, and plan to submit the IND to the FDA as soon as the GMP production of the Ii-Key vaccine is completed in the coming weeks. The Ii-Key vaccine is designed to be a Complete Vaccine, and we believe that our technology offers the safest and best route to ensure long-term immunity through T cell activation by the Ii-Key-SARS-CoV-2 epitopes in our vaccine formulation. Also, as there are still many questions surrounding long-term immunity after COVID, we plan to test the Ii-Key vaccine in people who have been previously infected with coronavirus to determine if vaccination with the Ii-Key vaccine can activate the T cell immune response to generate long-term immune memory.
Throughout the history of Generex’s Ii-Key vaccine development, several clinical trials have shown that Generex’s Ii-Key cancer vaccine is safe and promotes long-term immune memory. The safety of our Ii-Key vaccine platform is recognized by the FDA, as we do not require animal toxicology studies before we enter human trials with the Ii-Key COVID-19 vaccine. We have shown 3-year immune memory with our Ii-Key-HER-2 vaccine AE37 in breast and prostate cancer. Further, in preclinical studies of the Ii-Key-GP100 HIV vaccine, we showed that an Ii-Key booster can enhance the potency of a DNA vaccine through T cell activation. So, it must be noted that even if people get vaccinated with the current RNA and DNA vaccines, there are serious questions about their long-term effectiveness with manufacturers considering the need for annual booster shots. Because the Ii-Key vaccine is a targeted booster that is designed to provide long-term immunity through T cell activation, there is a major market opportunity to be a universal booster shot not only for vaccinated people, but also for COVID patients. Plus, with only 13% of the U.S. population vaccinated to date, and with the international market that is in dire need of vaccines, there is substantial unmet need in the marketplace. COVID is not going away.”
Mr. Moscato continued, “In addition to our work on the Ii-Key vaccine, we are very excited by the opportunity to license a series of therapeutic antibodies from a major research institute. We have signed confidentiality agreements and look forward to productive discussions to finalize a licensing agreement to initiate the clinical development of COVID-19 therapeutic solutions.”
Definitely truth in that but GNBT will follow, eventually.
Congratulations for what?
I guess the only shares selling "pre-IPO" are the shares shareholders already own that have no restrictions. Depending on the price you pay and the price the IPO will be, you may or may not be taking a big risk.
How is it possible for folks to buy & sell NUGX stock today if the IPO for NUGX has not even happened yet?
Was this IPO’d? Why is it trading, Shouldn’t there be an IPO price?
Followers
|
10
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
121
|
Created
|
03/15/21
|
Type
|
Free
|
Moderators |
NuGenerex Immuno-Oncology, Inc. is a platform biotechnology company focused on harnessing the power of the innate immune system to treat cancer and infectious disease with a pipeline of immunotherapy indications based on our proprietary, patented platform technology, Ii-Key.
The Company’s lead immunotherapy product candidate is
AE37, an Ii-Key-HER2 peptide vaccine for breast, prostate, and bladder cancer which incorporates our li-peptide linker to a designated antigen that activates the immune system targeting specific cancer cells. Ex-Vivo human studies are currently underway for our Ii-Key-SARS-CoV-2 vaccine and clinical trials are expected to begin in early 2021.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |